Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines
07 mars 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
02 mars 2022 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis
28 févr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment--9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period--No...
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
17 févr. 2022 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial
07 févr. 2022 07h00 HE
|
Evelo Biosciences, Inc.
Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cellsCytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation throughout the...
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases
17 janv. 2022 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts
04 janv. 2022 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Added to Nasdaq Biotechnology Index
14 déc. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
09 nov. 2021 07h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered...
Evelo Biosciences Reports Third Quarter 2021 Financial Results and Business Highlights
28 oct. 2021 07h00 HE
|
Evelo Biosciences, Inc.
–Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studies––Dosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021––Preclinical data...